Back
ESC Premium Access

Future direction for research in Empaglifozinon heart failure treatment.

Session: A perspective on the effects of Empaglifozin in cardiovascular outcomes
Topic: Drug therapy
Speaker: Associate Professor P. Sarafidis (Thessaloniki, GR)
Event: ESC Congress 2016

Congress Presentation

About the speaker

Associate Professor Pantelis Sarafidis

Aristotle University of Thessaloniki, Thessaloniki (Greece)
2 presentations
0 follower

4 more presentations in this session

State of the art in Empaglifozin in cardiovascular outcomes.

Speaker: Doctor D. Fitchett (Toronto, CA)

Access
Slides
Video
Thumbnail

Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME

Speaker: Doctor P. Monteiro (Coimbra, PT)

Access
Abstract
Slides
Video
Thumbnail

Cardiovascular outcomes according to LDL cholesterol levels in EMPA-REG OUTCOME

Speaker: Doctor G. Langslet (Oslo, NO)

Access
Abstract
Slides
Video
Thumbnail

Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME

Speaker: Professor D. Fitchett (Toronto, CA)

Access
Abstract
Slides
Video
Thumbnail

Access the full session

A perspective on the effects of Empaglifozin in cardiovascular outcomes

Speakers: Associate Professor P. Sarafidis, Doctor D. Fitchett, Doctor P. Monteiro, Doctor G. Langslet, Professor D. Fitchett
Access
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb